5. Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-...
参考文献: [1].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®):non-Small-Cell Lung Carcinoma 2022V3. [2].Zhou CC, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as ...
Squamous cell carcinomaTargeted therapiesGenetic alterationsTailored treatmentLung cancer is the leading cause of cancer-related death worldwide, and squamous cell carcinoma is the second most frequent histological subtype. The improvement registered in the last years in the treatment of non-small cell ...
[8]. He X, et al. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. J Immunother Cancer. 2020;8(2):e000807. [9]. Zhou C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy...
按照病理分型不同,将肺癌分成小细胞肺癌(英文全称为small-cell lung cancer,缩写为SCLC)和非小细胞肺癌(英文全称为nonsmall-cell lung cancer,缩写为NSCLC)。NSCLC包括几个亚型,最常见的三个亚型是腺癌(adenocarcinoma)、鳞癌(squamous cell carcinoma)和大细胞癌(large cell carcinoma)。NSCLC是最为常见的,是一种起...
[1]Rini BI, Powles T, Atkins MB, et al; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151):a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393 (10189):2404-241...
2.Campbell JD,Alexandrov A,Kim J,et al.Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas[J].Nat Genet,2016,48(6):607-16. 3.Gao W,Jin J,Yin J,et al.KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients[J].Mol...
Immunohistochemical algorithm for differentiation oflung adenocarcinoma and squamous cell carcinoma based on large series ofwhole-tissue sections with validation in small specimens. Mod Pathol, 2011,24(10): 1348-1359. [4] NONAKAD. A study of DeltaNp63 expression in lung non-small cell carcinomas....
squamous cell carcinomaDysregulation of microRNAs is a common mechanism in the development of lung cancer, but the relationship between microRNAs and expression subtypes in non‐small‐cell lung cancer (NSCLC) is poorly explored. Here, we analyzed microRNA expression from 241 NSCLC samples and ...
“Today’s approval expands our current lung cancer indications to include combination treatment in patients with squamous cell carcinoma, a type of lung cancer that is particularly difficult to treat,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “Approval by the FDA has...